Analyst Reco. Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.9 ^USD	-4.52%		-2.56%	-36.45%

Mar. 25	Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	DJ
Mar. 25	Sector Update: Health Care Stocks Steady Premarket Monday	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on Esperion Therapeutics to $9 From $10, Maintains Buy Rating	23-08-02	MT
TD Cowen Cuts Esperion Therapeutics' Price Target to $8 From $10, Maintains Outperform Rating	23-08-01	MT
Northland Securities Upgrades Esperion Therapeutics to Market Perform From Underperform, Raises Price Target to $2 From $1	23-08-01	MT
BofA Securities Upgrades Esperion Therapeutics to Buy From Underperform, Adjusts Price Target to $4 From $1.25	23-06-15	MT
Needham Adjusts Esperion Therapeutics Price Target to $10 From $12, Maintains Buy Rating	23-05-09	MT
Morgan Stanley Trims Price Target on Esperion Therapeutics to $3 From $9, Maintains Equalweight Rating	23-03-20	MT
Northland Securities Downgrades Esperion Therapeutics to Underperform From Market Perform, Adjusts PT to $1 From $5	23-03-16	MT
Needham Adjusts Price Target on Esperion Therapeutics to $12 From $16, Maintains Buy Rating	23-03-16	MT
BofA Downgrades Esperion Therapeutics to Underperform From Neutral, Adjusts Price Target to $1.50 From $8	23-03-16	MT
Credit Suisse Upgrades Esperion Therapeutics to Neutral From Underperform, Sees Downside Risk As More Limited; Lifts PT to $7 From $6.50	23-03-07	MT
Needham Adjusts Esperion Therapeutics' Price Target to $16 From $12, Maintains Buy Rating	23-03-06	MT
JPMorgan Chase Adjusts Price Target on Esperion Therapeutics to $9 From $8, Maintains Neutral Rating	23-02-27	MT
BofA Securities Reinstates Esperion Therapeutics at Neutral With $8 Price Target	23-02-27	MT
Morgan Stanley Upgrades Esperion Therapeutics to Equal Weight From Underweight, $9 Price Target	23-02-03	MT
Morgan Stanley Adjusts Price Target on Esperion Therapeutics to $9 From $7, Keeps Underweight Rating	22-11-02	MT
Credit Suisse Downgrades Esperion Therapeutics to Underperform from Neutral Given Relative Risk/Reward for Shares, Trims PT to $6 from $7	22-08-03	MT
Morgan Stanley Raises Esperion Therapeutics' Price Target to $7 From $5, Maintains Underweight Rating	22-07-15	MT
JPMorgan Upgrades Esperion Therapeutics to Neutral From Underweight; Price Target is $6	22-05-05	MT
HC Wainwright Initiates Esperion Therapeutics at Buy With $22 Price Target	22-03-10	MT
Credit Suisse Lowers Esperion Therapeutics' PT to $6 from $8 After Adjusting Near-Term Ramp in Bempedoic Acid Franchise Sales within Model; Keeps Neutral Rating	22-01-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Analyst Reco.

Filters